Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety
This study aimed to describe patient characteristics, treatment efficacy, and safety in patients with hepatocellular carcinoma (HCC) undergoing stereotactic body radiation therapy (SBRT). We retrospectively analyzed data of 318 patients with 375 HCC treated between June 2007 and December 2018. Effic...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/16/3892 |
| _version_ | 1797410987477827584 |
|---|---|
| author | Isaure Roquette Emilie Bogart Thomas Lacornerie Massih Ningarhari Jean-Emmanuel Bibault Marie-Cecile Le Deley Eric F. Lartigau David Pasquier Xavier Mirabel |
| author_facet | Isaure Roquette Emilie Bogart Thomas Lacornerie Massih Ningarhari Jean-Emmanuel Bibault Marie-Cecile Le Deley Eric F. Lartigau David Pasquier Xavier Mirabel |
| author_sort | Isaure Roquette |
| collection | DOAJ |
| description | This study aimed to describe patient characteristics, treatment efficacy, and safety in patients with hepatocellular carcinoma (HCC) undergoing stereotactic body radiation therapy (SBRT). We retrospectively analyzed data of 318 patients with 375 HCC treated between June 2007 and December 2018. Efficacy (overall survival [OS], relapse-free survival, and local control) and acute and late toxicities were described. The median follow-up period was 70.2 months. Most patients were treated with 45 Gy in three fractions. The median (range) PTV volume was 90.7 (2.6–1067.6) cc. The local control rate at 24 and 60 months was 94% (91–97%) and 94% (91–97%), respectively. Relapse-free survival at 12, 24, and 60 months was 62% (55–67%), 29% (23–36%), and 13% (8–19%), respectively. OS at 12, 24, and 60 months was 72% (95%CI 67–77%), 44% (38–50%), and 11% (7–15%), respectively. Approximately 51% and 38% experienced acute and late toxicity, respectively. Child-Pugh score B-C, high BCLC score, portal thrombosis, high GTV volume, and higher PTV volume reported on total hepatic volume ratio were significantly associated with OS. SBRT is efficient for the management of HCC with a favorable toxicity profile. The outcome is highly related to the natural evolution of the underlying cirrhosis. |
| first_indexed | 2024-03-09T04:38:28Z |
| format | Article |
| id | doaj.art-cbe325604c5d461a8766a1b478e462ee |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T04:38:28Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-cbe325604c5d461a8766a1b478e462ee2023-12-03T13:24:42ZengMDPI AGCancers2072-66942022-08-011416389210.3390/cancers14163892Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and SafetyIsaure Roquette0Emilie Bogart1Thomas Lacornerie2Massih Ningarhari3Jean-Emmanuel Bibault4Marie-Cecile Le Deley5Eric F. Lartigau6David Pasquier7Xavier Mirabel8Academic Department of Radiation Oncology, Centre Oscar Lambret, 59020 Lille, FranceDepartment of Biostatistics, Centre Oscar Lambret, 59020 Lille, FranceDepartment of Medical Physics, Centre Oscar Lambret, 59020 Lille, FranceDepartment of Hepatogastroenterology, CHU Lille, 59020 Lille, FranceInserm UMR 1138 Lab, Centre de Recherche des Cordeliers, Medical Informatics Unit, George Pompidou European Hospital, 75006 Paris, FranceDepartment of Biostatistics, Centre Oscar Lambret, 59020 Lille, FranceAcademic Department of Radiation Oncology, Centre Oscar Lambret, 59020 Lille, FranceAcademic Department of Radiation Oncology, Centre Oscar Lambret, 59020 Lille, FranceAcademic Department of Radiation Oncology, Centre Oscar Lambret, 59020 Lille, FranceThis study aimed to describe patient characteristics, treatment efficacy, and safety in patients with hepatocellular carcinoma (HCC) undergoing stereotactic body radiation therapy (SBRT). We retrospectively analyzed data of 318 patients with 375 HCC treated between June 2007 and December 2018. Efficacy (overall survival [OS], relapse-free survival, and local control) and acute and late toxicities were described. The median follow-up period was 70.2 months. Most patients were treated with 45 Gy in three fractions. The median (range) PTV volume was 90.7 (2.6–1067.6) cc. The local control rate at 24 and 60 months was 94% (91–97%) and 94% (91–97%), respectively. Relapse-free survival at 12, 24, and 60 months was 62% (55–67%), 29% (23–36%), and 13% (8–19%), respectively. OS at 12, 24, and 60 months was 72% (95%CI 67–77%), 44% (38–50%), and 11% (7–15%), respectively. Approximately 51% and 38% experienced acute and late toxicity, respectively. Child-Pugh score B-C, high BCLC score, portal thrombosis, high GTV volume, and higher PTV volume reported on total hepatic volume ratio were significantly associated with OS. SBRT is efficient for the management of HCC with a favorable toxicity profile. The outcome is highly related to the natural evolution of the underlying cirrhosis.https://www.mdpi.com/2072-6694/14/16/3892stereotactic body radiation therapyhepatocellular carcinomaSBRTHCCradiotherapy |
| spellingShingle | Isaure Roquette Emilie Bogart Thomas Lacornerie Massih Ningarhari Jean-Emmanuel Bibault Marie-Cecile Le Deley Eric F. Lartigau David Pasquier Xavier Mirabel Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety Cancers stereotactic body radiation therapy hepatocellular carcinoma SBRT HCC radiotherapy |
| title | Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety |
| title_full | Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety |
| title_fullStr | Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety |
| title_full_unstemmed | Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety |
| title_short | Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety |
| title_sort | stereotactic body radiation therapy for the management of hepatocellular carcinoma efficacy and safety |
| topic | stereotactic body radiation therapy hepatocellular carcinoma SBRT HCC radiotherapy |
| url | https://www.mdpi.com/2072-6694/14/16/3892 |
| work_keys_str_mv | AT isaureroquette stereotacticbodyradiationtherapyforthemanagementofhepatocellularcarcinomaefficacyandsafety AT emiliebogart stereotacticbodyradiationtherapyforthemanagementofhepatocellularcarcinomaefficacyandsafety AT thomaslacornerie stereotacticbodyradiationtherapyforthemanagementofhepatocellularcarcinomaefficacyandsafety AT massihningarhari stereotacticbodyradiationtherapyforthemanagementofhepatocellularcarcinomaefficacyandsafety AT jeanemmanuelbibault stereotacticbodyradiationtherapyforthemanagementofhepatocellularcarcinomaefficacyandsafety AT mariececileledeley stereotacticbodyradiationtherapyforthemanagementofhepatocellularcarcinomaefficacyandsafety AT ericflartigau stereotacticbodyradiationtherapyforthemanagementofhepatocellularcarcinomaefficacyandsafety AT davidpasquier stereotacticbodyradiationtherapyforthemanagementofhepatocellularcarcinomaefficacyandsafety AT xaviermirabel stereotacticbodyradiationtherapyforthemanagementofhepatocellularcarcinomaefficacyandsafety |